Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesetaxel in advanced breast cancer (CONTESSA TRIO)
NCT03952325Phase 2Terminated
- Sponsor
- Odonate Therapeutics
- Start
- Jul 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of tesetaxel in breast cancer, sponsored by Odonate Therapeutics. Primary endpoints: Objective Response Rate in PD-L1 Positive Patients, Progression Free Survival in PD-L1 Positive Patients and 2 more. Started Jul 2019; status: terminated.
02
Drugs
tesetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03952325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03952325.